Nurix Therapeutics (NRIX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $24.42, -2.12% vs the prior close of $24.95.
- Volume 3.69M shares, 2.4x its 50-day average (heavy).
- New SEC filings: 4 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
NRIX dips 2.1% to $24.42 on 2.4x normal volume. Closed at $24.42, -2.12% vs the prior close of $24.95. Day range $24.26–$25.35, opened at $24.85.
NRIX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NRIX dips 2.1% to $24.42 on 2.4x normal volume
- Closed at $24.42, -2.12% vs the prior close of $24.95. Day range $24.26–$25.35, opened at $24.85.
- Volume was 3.69M shares, 2.4x its 50-day average of 1.54M — unusually heavy trading.
- Price is -2.7% vs its 50-day average ($25.10) and +23.4% vs its 200-day average ($19.79).
- 52-week range $9.71–$28.23; today's close sits at 79% of that range, 13.5% below the 52-week high.
Oct 15, 2026 — NRIX jumps 5.4% to $24.95 on 2.5x normal volume
- Closed at $24.95, +5.41% vs the prior close of $23.67. Day range $23.61–$25.14, opened at $23.67.
- Volume was 3.75M shares, 2.5x its 50-day average of 1.49M — unusually heavy trading.
- Price is -0.6% vs its 50-day average ($25.11) and +26.2% vs its 200-day average ($19.77).
- 52-week range $9.18–$28.23; today's close sits at 83% of that range, 11.6% below the 52-week high.
Oct 14, 2026 — NRIX jumps 7.0% to $23.67 on 2.7x normal volume
- Closed at $23.67, +6.96% vs the prior close of $22.13. Day range $21.40–$24.01, opened at $22.01.
- Volume was 3.82M shares, 2.7x its 50-day average of 1.43M — unusually heavy trading.
- Price is -5.8% vs its 50-day average ($25.12) and +19.9% vs its 200-day average ($19.74).
- 52-week range $9.14–$28.23; today's close sits at 76% of that range, 16.2% below the 52-week high.
Oct 13, 2026 — NRIX ends flat (-0.1%) to $22.13, a 3-month low on 3.4x normal volume
- Closed at $22.13, -0.14% vs the prior close of $22.16. Day range $21.75–$23.24, opened at $22.16.
- Volume was 4.68M shares, 3.4x its 50-day average of 1.37M — unusually heavy trading.
- Price is -12.0% vs its 50-day average ($25.14) and +12.2% vs its 200-day average ($19.72).
- 52-week range $9.00–$28.23; today's close sits at 68% of that range, 21.6% below the 52-week high.
- SEC filings that day: 10-Q, 8-K.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 12, 2026 — NRIX dips 0.9% to $22.16, a 3-month low on 2.1x normal volume
- Closed at $22.16, -0.85% vs the prior close of $22.35. Day range $22.02–$22.58, opened at $22.27.
- Volume was 2.85M shares, 2.1x its 50-day average of 1.33M — unusually heavy trading.
- Price is -11.9% vs its 50-day average ($25.16) and +12.5% vs its 200-day average ($19.70).
- 52-week range $9.00–$28.23; today's close sits at 68% of that range, 21.5% below the 52-week high.
Oct 9, 2026 — NRIX rises 0.6% to $22.35
- Closed at $22.35, +0.63% vs the prior close of $22.21. Day range $21.23–$23.23, opened at $22.04.
- Volume was 1.53M shares, 1.2x its 50-day average of 1.32M.
- Price is -11.2% vs its 50-day average ($25.18) and +13.5% vs its 200-day average ($19.69).
- 52-week range $9.00–$28.23; today's close sits at 69% of that range, 20.8% below the 52-week high.
Oct 8, 2026 — NRIX dips 2.3% to $22.21, a 3-month low on 1.8x normal volume
- Closed at $22.21, -2.29% vs the prior close of $22.73. Day range $21.55–$22.60, opened at $22.49.
- Volume was 2.34M shares, 1.8x its 50-day average of 1.30M — unusually heavy trading.
- Price is -11.9% vs its 50-day average ($25.20) and +12.9% vs its 200-day average ($19.67).
- 52-week range $9.00–$28.23; today's close sits at 69% of that range, 21.3% below the 52-week high.
Oct 7, 2026 — NRIX rises 0.6% to $22.73
- Closed at $22.73, +0.58% vs the prior close of $22.60. Day range $22.18–$23.10, opened at $22.43.
- Volume was 1.63M shares, 1.3x its 50-day average of 1.29M.
- Price is -9.9% vs its 50-day average ($25.23) and +15.6% vs its 200-day average ($19.65).
- 52-week range $9.00–$28.23; today's close sits at 71% of that range, 19.5% below the 52-week high.
Oct 6, 2026 — NRIX dips 1.2% to $22.60, a 3-month low, 4 down days in a row
- Closed at $22.60, -1.22% vs the prior close of $22.88. Day range $22.10–$23.06, opened at $23.06.
- Volume was 1.15M shares, 0.9x its 50-day average of 1.29M.
- Price is -10.5% vs its 50-day average ($25.26) and +15.1% vs its 200-day average ($19.63).
- 52-week range $9.00–$28.23; today's close sits at 71% of that range, 19.9% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — NRIX dips 0.5% to $22.88, a 1-month low, 3 down days in a row
- Closed at $22.88, -0.48% vs the prior close of $22.99. Day range $22.42–$23.31, opened at $22.81.
- Volume was 1.01M shares, 0.8x its 50-day average of 1.29M.
- Price is -9.5% vs its 50-day average ($25.28) and +16.7% vs its 200-day average ($19.61).
- 52-week range $8.99–$28.23; today's close sits at 72% of that range, 19.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — NRIX dips 1.5% to $22.99, a 1-month low
- Closed at $22.99, -1.50% vs the prior close of $23.34. Day range $22.85–$23.75, opened at $23.72.
- Volume was 815.50K shares, 0.6x its 50-day average of 1.29M.
- Price is -9.1% vs its 50-day average ($25.29) and +17.4% vs its 200-day average ($19.59).
- 52-week range $8.85–$28.23; today's close sits at 73% of that range, 18.6% below the 52-week high.
NRIX latest news & SEC filings
Every SEC filing by or about NRIX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hansen Gwenn converted options/RSUs into 1,452 shares at $1.86 (≈$2.70K) on Oct 15, 2026; now holds 118,679
- Hansen Gwenn sold 1,452 shares at $25.00 (≈$36.30K) on Oct 15, 2026; now holds 117,227
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gregory Julia P converted options/RSUs into 22,583 shares at $1.86 (≈$42.00K) on Oct 14, 2026; now holds 33,333
- Gregory Julia P sold 22,583 shares at $23.40 (≈$528.53K) on Oct 14, 2026; now holds 10,750
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Aug 31, 2026:
- Revenue: $673.06M (prior year $7.89M) (+8426.3% vs Aug 31, 2025)
- Net income: $549.81M (prior year -$86.42M) (swung to profit vs Aug 31, 2025)
- Diluted EPS: $4.73 (prior year -$1.03) (swung to profit vs Aug 31, 2025)
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ring Christine converted options/RSUs into 5,786 shares at $8.72 (≈$50.45K) on Oct 2, 2026; now holds 14,896
- Ring Christine sold 5,786 shares at $23.19 (≈$134.15K) on Oct 2, 2026; now holds 9,110
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 23, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ring Christine sold 400 shares at $26.64 (≈$10.66K) on Sep 2, 2026
- Ring Christine sold 5,387 shares at $25.69 (≈$138.39K) on Sep 2, 2026
- Ring Christine sold 400 shares at $26.64 (≈$10.66K) on Sep 2, 2026
- Ring Christine sold 5,387 shares at $25.69 (≈$138.39K) on Sep 2, 2026
- Ring Christine sold 400 shares at $26.64 (≈$10.66K) on Sep 2, 2026
- Ring Christine sold 5,387 shares at $25.69 (≈$138.39K) on Sep 2, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade NRIX
- Last results release: Oct 13, 2026 (8-K Item 2.02). Previous ones: Jul 9, 2026, Apr 8, 2026, Jan 28, 2026. Based on that rhythm, the next report is likely around Jan 12, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.93% (largest 7.0%).
- Liquidity: about 2.14M shares (≈$52.33M) trade per day on average.
- 52-week position: $24.42 vs a range of $9.71–$28.23 (79% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Christine Ring sold 400 shares on Sep 2, 2026.
- Latest filings: 10-Q Oct 13, 2026; 8-K Oct 13, 2026; 10-Q Jul 9, 2026.
- Share count: 109.25M shares outstanding (Sep 30, 2026), +42.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NRIX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 24.85 | 25.35 | 24.26 | 24.42 | 3.69M |
| Oct 15, 2026 | 23.67 | 25.14 | 23.61 | 24.95 | 3.75M |
| Oct 14, 2026 | 22.01 | 24.01 | 21.40 | 23.67 | 3.82M |
| Oct 13, 2026 | 22.16 | 23.24 | 21.75 | 22.13 | 4.68M |
| Oct 12, 2026 | 22.27 | 22.58 | 22.02 | 22.16 | 2.85M |
| Oct 9, 2026 | 22.04 | 23.23 | 21.23 | 22.35 | 1.53M |
| Oct 8, 2026 | 22.49 | 22.60 | 21.55 | 22.21 | 2.34M |
| Oct 7, 2026 | 22.43 | 23.10 | 22.18 | 22.73 | 1.63M |
| Oct 6, 2026 | 23.06 | 23.06 | 22.10 | 22.60 | 1.15M |
| Oct 5, 2026 | 22.81 | 23.31 | 22.42 | 22.88 | 1.01M |
| Oct 2, 2026 | 23.72 | 23.75 | 22.85 | 22.99 | 815.50K |
| Oct 1, 2026 | 23.60 | 23.99 | 23.21 | 23.34 | 1.33M |
| Sep 30, 2026 | 23.85 | 23.94 | 23.34 | 23.71 | 2.01M |
| Sep 29, 2026 | 23.57 | 23.91 | 23.25 | 23.67 | 2.28M |
| Sep 28, 2026 | 22.86 | 23.69 | 22.41 | 23.67 | 2.01M |
| Sep 25, 2026 | 23.78 | 23.81 | 22.98 | 23.01 | 1.54M |
| Sep 24, 2026 | 23.76 | 23.93 | 23.01 | 23.65 | 2.02M |
| Sep 23, 2026 | 25.49 | 25.56 | 23.85 | 23.88 | 1.36M |
| Sep 22, 2026 | 25.32 | 25.96 | 25.23 | 25.67 | 1.51M |
| Sep 21, 2026 | 25.73 | 25.92 | 25.06 | 25.41 | 1.52M |
About Nurix Therapeutics
Nurix Therapeutics (NRIX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BRISBANE, CA. State of incorporation: DE. Fiscal year ends November 30. SEC CIK 1549595.
NRIX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Roy D. Baynes | Director | May 15, 2026 |
| Roger D Dansey | Director | May 15, 2026 |
| Julia P Gregory | Director | May 15, 2026 |
| Anil Kapur | Director | May 15, 2026 |
| David L. Lacey | Director | May 15, 2026 |
| Judith A Reinsdorf | Director | May 15, 2026 |
| Arthur T Sands | President, CEO | Feb 10, 2026 |
| Edward C Saltzman | Director | May 15, 2026 |
| Paul M Silva | Director | May 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gwenn Hansen | Chief Scientific Officer | Sep 1, 2026 |
| Christine Ring | Chief Legal Officer | Sep 2, 2026 |
| Arthur T Sands | President, CEO | Feb 10, 2026 |
| Houte Hans Van | Chief Financial Officer | Aug 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Christine Ring | Sale | 400 | $26.64 |
| Sep 2, 2026 | Christine Ring | Sale | 5,387 | $25.69 |
| Sep 2, 2026 | Christine Ring | Sale | 400 | $26.64 |
| Sep 2, 2026 | Christine Ring | Sale | 5,387 | $25.69 |
| Sep 2, 2026 | Christine Ring | Sale | 400 | $26.64 |
| Sep 2, 2026 | Christine Ring | Sale | 5,387 | $25.69 |
| Sep 2, 2026 | Christine Ring | Sale | 400 | $26.64 |
| Sep 2, 2026 | Christine Ring | Sale | 5,387 | $25.69 |
| Sep 1, 2026 | Gwenn Hansen | Sale | 1,452 | $25.47 |
| Sep 1, 2026 | Gwenn Hansen | Sale | 1,452 | $25.47 |
| Sep 1, 2026 | Gwenn Hansen | Sale | 1,452 | $25.47 |
| Sep 1, 2026 | Gwenn Hansen | Sale | 1,452 | $25.47 |
| Aug 5, 2026 | Gwenn Hansen | Sale | 4,356 | $25.00 |
| Aug 5, 2026 | Gwenn Hansen | Sale | 4,356 | $25.00 |
| Aug 5, 2026 | Gwenn Hansen | Sale | 4,356 | $25.00 |
NRIX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Nov 30, 2025 | $83.98M | $-264.46M | -3.05 | $-249.47M |
| Nov 30, 2024 | $54.55M | $-193.57M | -2.88 | $-172.58M |
| Nov 30, 2023 | $76.99M | $-143.95M | -2.65 | $-81.36M |
| Nov 30, 2022 | $38.63M | $-180.36M | -3.71 | $-159.81M |
| Nov 30, 2021 | — | $-117.19M | -2.73 | $-84.36M |
Latest balance sheet: total assets $1.20B, total liabilities $226.99M, cash $720.24M (as of Aug 31, 2026).
NRIX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 13, 2026 | 8-K Item 2.02 (results) | $22.13 |
| Jul 9, 2026 | 8-K Item 2.02 (results) | $24.69 |
| Apr 8, 2026 | 8-K Item 2.02 (results) | $15.60 |
| Jan 28, 2026 | 8-K Item 2.02 (results) | $17.87 |
| Oct 9, 2025 | 8-K Item 2.02 (results) | $10.86 |
| Jul 9, 2025 | 8-K Item 2.02 (results) | $13.18 |
| Apr 8, 2025 | 8-K Item 2.02 (results) | $9.26 |
| Jan 28, 2025 | 8-K Item 2.02 (results) | $19.56 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $19.01 |
| Oct 11, 2024 | 8-K Item 2.02 (results) | — |
| Jul 11, 2024 | 8-K Item 2.02 (results) | — |
| Apr 10, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NRIX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.